Insurers take different approaches to costly GLP-1 drugs
CVS Health will prioritize Wegovy over Zepbound starting July 1, dropping Eli Lilly's GLP-1 drug from its main commercial formulary. The move reflects diverging insurer strategies…
CVS Health will prioritize Wegovy over Zepbound starting July 1, dropping Eli Lilly's GLP-1 drug from its main commercial formulary. The move reflects diverging insurer strategies…